The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
This article reviews the role of trastuzumab in managing HER2-positive breast cancer in the preoperative, postoperative, and metastatic settings and confronts the emerging problem of trastuzumab resistance.
Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting. This is a modal window. The Playback API request failed for an unknown reason Error Code: ...
[8] Spring LM, Barlow WE, Bardia A, et al. Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Anton...
The overexpression of human epidermal growth factor receptor-2 (HER2) results in a biologically and clinically aggressive breast cancer (BC) subtype. Since the introduction of anti-HER2 targeted agents, survival rates of patients with HER2-positive metastatic BC have dramatically improved. Currently, ...
breastpositive乳腺癌trastuzumab阳性pertuzumab Series.thelancetPublishedonlineDecember6,2016http://dx.doi/10.1016/S0140-6736(16)32417-51Breastcancer2HER2-positivebreastcancerSibylleLoibl,LucaGianniAnti-HER2treatmentforHER2-positivebreastcancerhaschangedthenaturalbiologyofthisdisease.ThisSeriesarticlereviewsthemainachie...
of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ breast cancer. ...
5. Gingras I, Gebhart G, De Azambuja E & Piccart-Gebhart M 2017 HER2positive breast cancer is lost in translation: time for patient-centered research. Nature Reviews: Clinical Oncology 14 669-681. 6. Li LT, Jiang ...
Piccart M J ,et al.Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer[J].European journal of cancer: official journal for European Organization for Research and Treatment of Ca...
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...